Get started
Author

Gautham Gampa

Special Section on Pharmacokinetic and Drug Metabolism Properties of Novel Therapeutic Modalities–Minireview
2019 · Donglu Zhang, Cornelis E.C.A. Hop, et al. · Drug Metabolism and Disposition · 121
PDF
Barriers to Effective Drug Treatment for Brain Metastases: A Multifactorial Problem in the Delivery of Precision Medicine
2018 · Minjee Kim, Sani H. Kizilbash, et al. · Pharmaceutical Research · 80
Drug delivery to melanoma brain metastases: Can current challenges lead to new opportunities?
2017 · Gautham Gampa, Shruthi Vaidhyanathan, et al. · Pharmacological Research · 49
Brain Distribution of a Novel MEK Inhibitor E6201: Implications in the Treatment of Melanoma Brain Metastases
2018 · Gautham Gampa, Minjee Kim, et al. · Drug Metabolism and Disposition · 29
PDF
E6201, an intravenous MEK1 inhibitor, achieves an exceptional response in BRAF V600E-mutated metastatic malignant melanoma with brain metastases
2018 · Hani M. Babiker, Sara A. Byron, et al. · Investigational New Drugs · 28
NKG2D-bispecific enhances NK and CD8+ T cell antitumor immunity
2024 · Aurelie Herault, Judy Mak, et al. · Cancer Immunology Immunotherapy · 26
PDF
Enhancing Brain Retention of a KIF11 Inhibitor Significantly Improves its Efficacy in a Mouse Model of Glioblastoma
2020 · Gautham Gampa, Rajappa S. Kenchappa, et al. · Scientific Reports · 25
PDF
Brain Distribution and Active Efflux of Three panRAF Inhibitors: Considerations in the Treatment of Melanoma Brain Metastases
2019 · Gautham Gampa, Minjee Kim, et al. · Journal of Pharmacology and Experimental Therapeutics · 21
PDF
Challenges in the Delivery of Therapies to Melanoma Brain Metastases
2016 · Gautham Gampa, Shruthi Vaidhyanathan, et al. · Current Pharmacology Reports · 20
PDF
Preclinical modeling in glioblastoma patient-derived xenograft (GBM PDX) xenografts to guide clinical development of lisavanbulin—a novel tumor checkpoint controller targeting microtubules
2021 · Danielle M Burgenske, Surabhi Talele, et al. · Neuro-Oncology · 18
PDF
Brain Distributional Kinetics of a Novel MDM2 Inhibitor SAR405838: Implications for Use in Brain Tumor Therapy
2019 · Minjee Kim, Janice K. Laramy, et al. · Drug Metabolism and Disposition · 15
PDF
Bridging the blood-brain barrier: strategies to improve delivery of biologics to tumors in the brain
2026 · Gautham Gampa, Rahul Vadlakonda, et al. · Fluids and Barriers of the CNS · 12
In Vivo Efficacy of Tesevatinib in EGFR -Amplified Patient-Derived Xenograft Glioblastoma Models May Be Limited by Tissue Binding and Compensatory Signaling
2021 · Sani H. Kizilbash, Shiv K. Gupta, et al. · Molecular Cancer Therapeutics · 12
PDF
Preclinical and translational pharmacology of afucosylated anti‐CCR8 antibody for depletion of tumour‐infiltrating regulatory T cells
2024 · Gautham Gampa, Phillip Spinosa, et al. · British Journal of Pharmacology · 11
Development and Validation of a Stability Indicating Liquid Chromatographic Method for the Determination of Milnacipran in Bulk and its Formulations
2013 · Gautam Singhvi, Gautham Gampa, et al. · Current Pharmaceutical Analysis · 11
Development of a new, rapid and sensitive HPTLC method for estimation of Milnacipran in bulk, formulation and compatibility study
2013 · Gautam Singhvi, Vipin Kumar Shukla, et al. · Arabian Journal of Chemistry · 9
Design and Evaluation of Rapidly Disintegrating Tablets of Racecadotril with Enhanced in-vitro Dissolution Achieved by Solid Dispersion Technique
2013 · Gautam Singhvi, Gautham Gampa, et al. · Indian Journal of Pharmaceutical Education and Research · 6
PDF
Influence of transporters in treating cancers in the CNS
2019 · Gautham Gampa, Surabhi Talele, et al. · Elsevier eBooks · 4
Design of a Modified Kinetic Solubility Determination Method at Laboratory Level for Early Drug Discovery
2013 · Gautam Singhvi, Sachin Sonavane, et al. · Asian Journal of Chemistry · 2
Characterization of an anti-STEAP1 T-cell dependent bispecific antibody for the treatment of prostate cancer and associated toxicity in cynomolgus monkeys
2026 · Elizabeth G Tonkin, Michelle Lepherd, et al. · Toxicological Sciences
Development of a Unified QSP Framework to Characterize the Pharmacokinetics of TCBs
2026 · Narmada BC, Dinesh Bedathuru, et al.
Figure S1 from In Vivo Efficacy of Tesevatinib in EGFR-Amplified Patient-Derived Xenograft Glioblastoma Models May Be Limited by Tissue Binding and Compensatory Signaling
2023 · Sani H. Kizilbash, Shiv K. Gupta, et al.
Data from In Vivo Efficacy of Tesevatinib in EGFR-Amplified Patient-Derived Xenograft Glioblastoma Models May Be Limited by Tissue Binding and Compensatory Signaling
2023 · Sani H. Kizilbash, Shiv K. Gupta, et al.
Data from In Vivo Efficacy of Tesevatinib in EGFR-Amplified Patient-Derived Xenograft Glioblastoma Models May Be Limited by Tissue Binding and Compensatory Signaling
2023 · Sani H. Kizilbash, Shiv K. Gupta, et al.
Figure S1 from In Vivo Efficacy of Tesevatinib in EGFR-Amplified Patient-Derived Xenograft Glioblastoma Models May Be Limited by Tissue Binding and Compensatory Signaling
2023 · Sani H. Kizilbash, Shiv K. Gupta, et al.
PDF
Works count: 33
Citation count: 500
H-index: 12
I10-index: 15
Year
Topic
Type